Quetiapine augmentation to SRIs for patients with obsessive compulsive disorder: a double-blind, placebo-controlled study.
Completed
- Conditions
- Obsessive-Compulsive Disorder.
- Registration Number
- NL-OMON28722
- Lead Sponsor
- Prof. dr. H.G.M. WestenbergDepartment of PsychiatryUMC UtrechtHeidelberglaan 1003584 CX UtrechtThe NetherlandsPhone: +31 30 2509019E-mail: h.g.m.westenberg@azu.nl
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 90
Inclusion Criteria
1. All patients meet the DSM IV criteria for obsessive-compulsive disorder;
2. Y-BOCS score > 16 if obsessions and compulsions;
Exclusion Criteria
1. Presence of any of the following DSM IV conditions:
a. Major depression (with a HDRS>17, [17 item]);
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change in Yale Brown obsessive compulsive scale (Y-BOCS) from baseline to week 10 and the number of responders are the primary efficacy parameters.<br /> <br>Criteria for response will be a 25% or greater change from baseline on the Y-BOCS and a final CGI rating of much improved or very much improved.
- Secondary Outcome Measures
Name Time Method 1. The onset of response to treatment, using the time to a sustained response as criterion;<br /><br>2. Side effect profiles;<br /><br>3. Quality of life;<br /><br>4. Cognitive functioning.<br />